| Document |
Document Title |
|
WO/2020/159389A1 |
The subject of the invention comprises new compounds forming Van-TPlO conjugates, method of their preparation, composition and use in antibacterial treatment against Staphylococcus aureus, Enterococcus spp. and Neisseria spp.
|
|
WO/2020/150394A1 |
IL-17-producing γδ T cells and CD4+ TH17 cells were identified in fibrotic tissue surrounding human breast implants. In both murine and human tissue samples, senescent cells developed around the implants, which was linked to the IL-17 ...
|
|
WO/2020/124032A1 |
Described herein are peptides and variants thereof as well as peptide constructs comprising peptides conjugated to, linked to, or fused to agents, wherein the peptides and peptide constructs are capable of binding TfR. Binding of a pepti...
|
|
WO/2020/060491A1 |
The invention relates to a compound of formula la and/or formula lb: or a pharmaceutically acceptable salt, solvate or prodrug thereof, where the groups are defined herein. The invention also relates to a pharmaceutical formulation compr...
|
|
WO/2020/057422A1 |
A vancomycin derivative represented by general formula (I) and a pharmaceutically acceptable salt thereof, a preparation method for the vancomycin derivative, and uses of these compounds in preparation of medicaments for treating and/or ...
|
|
WO/2020/016855A1 |
Aberrant cross talk between Notch ligand (e.g. Jagl) and Notch receptor (e.g. Notch 1) has been implicated in tumorigenesis in the colon. Inhibition of Notch pathway is therefore an attractive approach for treating diseases with upregula...
|
|
WO/2019/227163A1 |
The present invention relates to peptides with alternating stereochemistry. In particular, the invention relates to peptides comprising alternating stereochemistry of (LDLD) in the first four amino acid residues. The invention further co...
|
|
WO/2019/170046A1 |
Disclosed are glycopeptide compounds having activity of resisting drug-resistant bacteria, conforming to glycopeptide compounds represented by general formula (I). The present invention also provides a preparation method for and an appli...
|
|
WO/2019/157233A1 |
Disclosed herein are compositions for assessing peptidoglycan (PG) biosynthesis in bacteria using modified D-amino acids covalently attached to a molecular rotor and visualizing the labeled PG in bacteria based upon the enhanced fluoresc...
|
|
WO/2019/122327A1 |
The present invention relates to a newly identified bio-surfactant producing bacterial strain, Bacillus subtilis QVS1, which was deposited under accession number LMG P-30406, and to fermentative processes wherein such a strain is employe...
|
|
WO/2019/122234A1 |
The present invention relates to recombinant polypeptide therapeutics having an engineered O-linked amino acid (AA) glycosylation sequence (motif), which is covalently linked to O-glycan(s) (tag). Recombinant O-glycosylated polypeptides ...
|
|
WO/2019/096234A1 |
As represented by formula I, a glycopeptide antibiotic compound having anti-drug-resistant bacteria activity or a pharmaceutically acceptable salt of same, a pharmaceutical preparation of same, a preparation method for same, and applicat...
|
|
WO/2018/217800A1 |
Provided herein are methods and compositions for the treatment of Gram positive bacterial infections. The infection in some embodiments, is a pulmonary infection. The method for treating the bacterial infection, comprises in one embodime...
|
|
WO/2018/209223A1 |
The present disclosure relates to the identification and application of adaptive immune receptor sequences that indicate an elevated risk of developing an adaptive immune receptor-related disease, such as an autoimmune disease (e.g., mul...
|
|
WO/2018/190776A1 |
The present invention provides compounds of formula (I), polymers and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said compounds, methods of preparing said compounds or pharmaceutical compositions, a...
|
|
WO/2018/150196A1 |
The present invention relates to peptides, in particular cell penetrating peptides, of 40 amino acid residues or less comprising at least one directly glycosylated amino acid residue and one or more arginine rich arm domains, and to conj...
|
|
WO/2018/129328A1 |
Compositions and methods for optically-verified, sequence-controlled polymer synthesis are described.
|
|
WO/2018/102889A1 |
A construct comprising: (i) an optionally derivatized glycopeptide antibiotic; (ii) a nanoparticle; and (iii) a first linker connecting (i) and (ii) is provided. The construct may further comprise a second linker located between the firs...
|
|
WO/2018/102890A1 |
A visualization construct comprising: (i) an optionally derivatized glycopeptide antibiotic; (ii) a visualization component; and (iii) a first linker connecting (i) and (ii) is provided. The visualization component may be a fluorescent c...
|
|
WO/2018/089858A1 |
The disclosed embodiments concern methods, devices, and systems for identifying candidate biomarkers useful for the diagnosis, prognosis, monitoring and screening and/or as targets for the treatment of diseases and conditions in subjects...
|
|
WO/2018/051291A1 |
The present technology relates to vaccine compositions comprising at least one of the nine peptides defined by SEQ ID NO 1-9, capable of stimulating the development of a T helper 1 (Th1)-type cell immune response with high production of ...
|
|
WO/2018/045889A1 |
Provided are a crystal form A of oritavancin diphosphate, and a preparation method and use thereof. The crystal form has excellent properties in the aspects of dissolution time, biological release, chemical stability, and processing adap...
|
|
WO/2018/037343A1 |
The present technology relates to vaccine compositions for the treatment and/or prevention of visceral leishmaniasis in mammals, comprising six synthetic peptides that are free or expressed in the surface of non-infectious bacteriophages...
|
|
WO/2018/031887A1 |
Methods and assays for detecting natalizumab in a sample, natalizumab-peptide complexes in a sample, and point-of-care devices for detecting natalizumab in a sample are described herein.
|
|
WO/2018/014005A1 |
The disclosure provides for multiple-reporter systems that are capable of rapidly and indirectly screening cells for a certain cell type and/or cell function.
|
|
WO/2018/010476A1 |
Provided are a glycopeptides based derivative represented by the general formula (I) and a pharmaceutically acceptable salt thereof. R1 is H, 2-alkylamine-ethyl group, a substituted benzyl group, a substituted phenylpropionyl group or a ...
|
|
WO/2018/010475A1 |
A glycopeptide derivative represented by the general formula (I) and a pharmaceutically acceptable salt thereof, R1 is H, 2-alkylamine-ethyl, a substituted benzyl group, a substituted phenylpropionyl group, or a linear acyl group contain...
|
|
WO/2017/186110A1 |
Provided are a class of vancomycin derivatives with a structure as shown in the general formula below, a preparation method, a pharmaceutical composition containing the compound thereof and the use of these compounds in preparing drugs f...
|
|
WO/2017/161909A1 |
The present invention relates to a preparation and purification method of a norvancomycin and a norvancomycin derivative. The method uses a salt-free liquid phase HPLC. The invention further relates to a method for acquiring the norvanco...
|
|
WO/2017/141961A1 |
The present invention addresses the problem of providing a means for making highly sensitive and stable measurements possible using electrochemical measurement methods. This problem is resolved by providing: a label represented by genera...
|
|
WO/2017/123912A1 |
Liquid vancomycin containing compositions having extended shelf life are disclosed. The compositions contain vancomycin or a pharmaceutically acceptable salt thereof, a polyol such as glycerol, and lactic acid or a lactate. The compositi...
|
|
WO/2017/112955A1 |
Provided herein, inter alia, are compositions and methods for generating a immune response in an individual and/or inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells via inhibition of nonsense...
|
|
WO/2017/103625A1 |
Provided is the use of inactivated FABP5 proteins, or fragments or variants thereof, as a medicament. These may be used in the treatment of a FABP5 mediated disorders, such as cancer. The inactivated FABP5 proteins, or fragments or varia...
|
|
WO/2017/105295A1 |
The invention relates to organic compound chemistry, pharmacology and medicine, and more particularly to developing and producing a novel medicinal agent for treating diseases caused by a human influenza virus. For this purpose, co-assoc...
|
|
WO/2017/098529A1 |
The invention relates to novel Muramyl Dipeptide (MDP) derivative compound of structural Formula-VIII, a process for synthesis, intermediates used in the synthesis and use thereof. R = alkyl (both linear and branched), aryl, substituted ...
|
|
WO/2017/083914A1 |
The present invention provides compounds for use in treating and/or preventing influenza. The compound comprises a first and second domain in which the first domain comprises at least one anchoring group which binds to the surface of inf...
|
|
WO/2017/020282A1 |
Provided is a multi-target compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism. The formula of the multi-target compound is as follows: A-L-B-L'-C. A and B are binding sites with a thrombin, C is a binding site with...
|
|
WO/2017/019952A1 |
Inflammatory cell recruitment to local sites of tissue injury and/or infection is controlled by many signaling processes influencing cell-to-cell interactions between vascular endothelial cells (EC) in post-capillary venules and circulat...
|
|
WO/2016/169010A1 |
Disclosed are a use of teicoplanin against the Ebola virus, and a medicine comprising teicoplanin for inhibiting envelope protein GP.
|
|
WO/2016/172615A1 |
The present invention provides N-acetyl-muramic acid (NAM) derivatives having Formula I, wherein Xa is selected from the group consisting of X1-X59, Ya is selected from the group consisting of H, monophosphate, uridine diphosphate and et...
|
|
WO/2016/135513A1 |
The present application relates to materials and methods for exploiting synthetic lethality and/or chemo-sensitisation in DNA damage response (DDR) pathways. In particular, the application relates to ubiquitin hydrolase protein Ubiquitin...
|
|
WO/2016/134622A1 |
Provided is a vancomycin derivative as shown in formula (I). Such compounds can be used for treating the infections of gram-positive bacteria or vancomycin-resistant bacteria, and can be prepared from vancomycin via a chemical synthesis ...
|
|
WO/2016/134485A1 |
The present application provides methods and uses of O-oligosaccharyltransferase (O-OTases) for generating vaccines. In particular, the present application provides a method of synthesizing a glycoprotein comprising glycosylation of pili...
|
|
WO/2016/136707A1 |
This polysaccharide derivative has a partial structure represented by general formula (1). It is preferable that at least one of the amino acids that constitutes X2 of general formula (1) is a basic amino acid. (In the formula, X1 repres...
|
|
WO/2016/125193A1 |
Vancomycin conjugates of Formula I, its stereoisomers, prodrugs, pharmaceutically acceptable salts, and metal coordination complexes thereof is described in the present disclosure. Further, the present disclosure relates to pharmaceutica...
|
|
WO/2016/120257A1 |
The present invention relates to compounds and compositions for use in enhancing flavor and umami taste of food products. Particularly, the present invention relates to compounds of the general formula I) and compositions comprising them.
|
|
WO/2016/120250A1 |
The present invention relates to compounds and compositions for use in enhancing flavor and umami taste of food products. Particularly, the present invention relates to compounds of the general formula (I) and compositions comprising them.
|
|
WO/2016/103284A1 |
The present disclosure provides a compound of Formula I or its stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. The present disclosure also relates to process of preparation of vancomycin-sugar conjugates of Formula...
|
|
WO/2016/065083A1 |
This disclosure provides a method for treating a gastro-esophageal injury in a patient by topically applying a pharmaceutical composition to a lesion on a gastro-esophageal tissue, wherein the pharmaceutical composition comprises an effe...
|
|
WO/2016/054114A1 |
Provided are compositions, including isolated, synthetic or recombinant peptides for: expanding regulatory T cells (Treg) populations; for treating or ameliorating a vascular inflammation, and Kawasaki disease (KD) or a pediatric acute v...
|
